Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. - Wikidata - awgldk - TriplyDB

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

http://www.wikidata.org/entity/Q36040754

about

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease Construction of drug network based on side effects and its application for drug repositioning Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase.Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.Anti-Parkinson's disease drugs and pharmacogenetic considerations.Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice.Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.Drug-Induced Mitochondrial Toxicity.Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats

P2860

Q24644555-7A6A4040-947A-4DB3-AE08-B92E33C9212C Q24657680-DE53B012-DC42-4F06-8C77-F468641CBA9B Q28539501-90377C4E-BFB5-4B71-9BDB-945D3A0400F1 Q30010969-848F4CAF-4CCB-4EBC-89D9-63A92FE8088E Q36227514-E741ADE1-37CC-4FBC-846A-DDD45677CCF1 Q37164701-229192F2-BA51-4B50-BB6E-9579A78156F8 Q38008438-75218D02-F393-4064-B03E-0CF0747D8068 Q38097097-F130F65C-F0A0-43B3-8972-9BE15747D8A7 Q38762256-E4D7777C-6953-40F6-99D9-6CCD95810CAF Q40092052-090D0F9E-AAFA-4CFD-AF29-ADA3551A5907 Q41367261-2078DF74-76F9-46B8-9441-317B97FC9491 Q47648607-8E7B5720-4B4B-4350-8A0F-8414C31B0982 Q51538858-7B22510F-0536-414C-9252-38414B572E40 Q57269385-B95E6270-B82A-4816-9FD9-9BBE58B4026F

P2860

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

http://www.wikidata.org/entity/Q36040754

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

@ast

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

@en

type

label

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

@ast

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

@en

prefLabel

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

@ast

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

@en

P1433

Q36040754-DDA2F5EA-BA0B-493A-8B77-511F3487AA43

P1476

Q36040754-6F1498F6-9122-4750-B806-CC76123987B5

P2093

Q36040754-4BC6C36B-7EDE-4F0D-904A-0FAC82DDD027

P2860

Q36040754-0EFC8108-B5FE-426F-B18F-551B199DD62E

Q36040754-2A49F15D-EB12-4F6C-9A70-0C31D18724A4

Q36040754-2A94C663-78F2-4677-8F22-561CF8441466

Q36040754-2F806771-402E-4E71-AA83-8DFB4E118A0D

Q36040754-34A0C249-766B-4CDA-B03D-DD4D0C786499

Q36040754-3D601FE7-A5C7-4AD6-881A-CD67090A8B05

Q36040754-6144E045-617C-4E7A-A51F-8961BB97A2D7

Q36040754-627E9EAF-73FA-467E-828A-C5B42D090D27

Q36040754-6758ECA1-4EB3-4FA2-A3BE-BF832350041C

Q36040754-6F3E2B40-04B2-4A4A-AC46-1AE631C2EEAE

P304

Q36040754-13DE0B19-79FD-4772-867E-54DF0EF4C3D5

P31

Q36040754-8176E1B8-18A2-44A8-B4A4-9D01D63735E0

P356

Q36040754-7D73612B-DF55-4E7F-B752-A7CCF75668AC

P407

Q36040754-B4A579FF-8721-43D7-BC0C-55AA1A920F86

P433

Q36040754-D43A535C-D3C5-469F-BEB0-74E35A6CB6D8

P478

Q36040754-A965277A-DBB8-4BA4-98FF-802480EBDBDB

P50

Q36040754-950864CB-94D5-4ADE-B286-2BFAD3A1AAA2

P577

Q36040754-023348CB-B6BD-49FF-B7FF-C0BEB9E48DCB

P698

Q36040754-1CB79FD2-7F0E-4612-AC04-EE4C7FCCC99F

P921

Q36040754-462828F5-CC38-4EF0-A8D7-E3E352A5A155

P356

14740338.4.1.69

P1433

Expert Opinion on Drug Safety

P1476

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy

@en

P2093

Nuno Borges

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.

The rise and fall of tolcapone.

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.

Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease.

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.

Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells.

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.

P304

69-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.4.1.69

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15709899

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease